v3.24.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Total net revenue $ 164,502 $ 146,917 $ 320,742 $ 284,137
COST OF REVENUE 92,008 87,026 182,779 169,432
GROSS PROFIT 72,494 59,891 137,963 114,705
Operating expenses:        
General and administrative 63,328 60,308 129,125 121,857
Research and development 7,886 7,502 15,506 14,897
Sales and marketing 21,677 18,901 41,898 35,160
Restructuring charges 1,544 3,074 3,942 7,758
Total operating expenses 94,435 89,785 190,471 179,672
LOSS FROM OPERATIONS (21,941) (29,894) (52,508) (64,967)
Interest income (4,592) (4,308) (9,426) (7,532)
Interest expense 1,666 1,784 3,351 3,541
Other expense (income), net 2 (730) 265 (616)
Loss before taxes (19,017) (26,640) (46,698) (60,360)
Income tax benefit (375) (2,309) (995) (5,234)
NET LOSS $ (18,642) $ (24,331) $ (45,703) $ (55,126)
NET LOSS PER SHARE        
Basic (in dollars per share) $ (0.15) $ (0.19) $ (0.36) $ (0.44)
Diluted (in dollars per share) $ (0.15) $ (0.19) $ (0.36) $ (0.44)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING        
Basic (in shares) 126,405 125,356 126,257 125,192
Diluted (in shares) 126,405 125,356 126,257 125,192
Clinical Services        
Total net revenue $ 141,388 $ 123,156 $ 275,923 $ 238,025
COST OF REVENUE 78,094 71,746 154,938 139,038
GROSS PROFIT 63,294 51,410 120,985 98,987
Advanced Diagnostics        
Total net revenue 23,114 23,761 44,819 46,112
COST OF REVENUE 13,914 15,280 27,841 30,394
GROSS PROFIT $ 9,200 $ 8,481 $ 16,978 $ 15,718

Source